MYCO-007 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.
[1] As of February 2024, it is in preclinical research.
[1] The chemical structure of MYCO-007 does not yet appear to have been disclosed.
[1] 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) were described in Mydecine's patent for short-acting MDMA analogues[6][7][8]
This psychoactive drug-related article is a stub.